News

For the past six years Mr Gonze was the COO at Unither Pharmacueticals. He has broad experience in all aspects of commercial operations having held senior level positions

Mr Hart comes to Emisphere with over 16 years of commercial experience in the pharmaceutical industry. In his most recent capacity at Organon, part of Schering Plough, he

Dr Ehlers served as chief medical officer since joining the company in September 2002. He is leaving to take up a position in academia. Dr Ehlers has agreed

Simultaneously, the company expanded its operations in China to increase MicuRx’s capacity in antibacterial drug discovery and development. To facilitate the development of its lead compounds and expand

A total of 123 subjects started treatment with 320mg Bronchitol twice per day and 99 subjects completed the full 12 months of the trial. Of the 24 withdrawals,

The new antibodies were announced as the latest additions to the Human Protein Atlas portal. Initially consisting of 1,800 antibodies, the portfolio has grown to over 3,800 antibodies

This agent is said to be the first product developed out of the Merck-VisEn Biomarker Imaging research collaboration announced in 2007, and will enable researchers to image and

Oral dnaJP1 is a once-daily epitope specific immunotherapy for rheumatoid arthritis (RA) patients. Oral dnaJP1 is a heat shock protein (hsp)-derived peptide which was previously identified as a

Covidien Ventures will be managed by Daniel Sheehan, vice president of Corporate Venture Capital, who recently joined Covidien from Affinity Capital Management. Mr Sheehan, who has 20 years